

B1
car

administering a composition wherein said composition is comprised of,
a hypocholesterolemic agent, wherein said hypocholesterolemic agent is selected
from the group consisting of benfluorex and ursodesoxycolic acid;
a hypotriglyceride agent, wherein said hypotriglyceride agent is benfluorex;
a lipasic and proteasic agent, wherein said lipasic and proteasic agent is
pancreatine IX F.U.;
a hypoglycemic agent, wherein said hypoglycemic agent is metformine; and
a hydrocoleretic agent, wherein said hydrocoleretic agent is selected from the
group consisting of Na dehydrocholate and ursodesoxycolic acid.

27. (New) The method as claimed in claim 1, wherein in said administration of
said composition, said composition further comprises at least one of:

a hypouricemic agent, wherein said hypouricemic agent is centella asiatica
purified triterpenes;

a radical scavenger agent, wherein said radical scavenger agent is selenium;

a sympatholytic agent, wherein said sympatholytic agent is [being preferably]
yohimbine;

a sympathicomimetic agent, wherein said sympathicomimetic agent is from the
group consisting of phendimetrazinum bitartrate and phendimetrazinum pamoate; and
at least one vitamin, wherein said at least one vitamin being selected from the
group consisting of vitamin A, vitamin B1, vitamin B6, vitamin E and Vitamin C.

28. (New) The method as claimed in claim 27, wherein in said administration of

said composition, said composition further comprises at least one diet adjuvant selected from the group consisting of sedative-anxiolytic agents, anorectic agents and lipolytic agents.

134
cont

29. (New) The method as claimed in claim 26, wherein in said administration of said composition, said benfluorex is present in global amount from 7% to 23% in weight of the total amount of the composition;

said pancreatine IX F.U. is present in an amount from 27% to 43% in weight of the total amount of the composition;

said metformine is present in an amount from 36% to 41% in weight of the total amount of the composition; and

said Na dehydrocloate is present in an amount from 9% to 14% of the total amount of the composition.

30. (New) The method as claimed in claim 26, wherein in said administration of said composition,

said benfluorex is present in an amount from 7% to 23% in weight of the total amount of the composition;

said pancreatine IX F.U. is present in an amount from 27% to 43% in weight of the total amount of the composition;

said metformine is present in an amount from 36% to 41% in weight of the total amount of the composition; and

said Ursodesoxycolic acid is present in an amount from 14% to 17% in weight of the total amount of the composition.

31. (New) The method as claimed in claim 27, wherein in said administration of
said composition, elements of said composition are in at least one of a set of ratios, said ratios
including the set of,

said centella asiatica purified triterpenes is in a ratio from 0.04:1 to 0.5:1 in
weight with respect to the total weight of composition;

said selenium is in a ratio from 0.09:1 to 0.3:1 in weight with respect to
the total weight of composition;

said yohimbine is in a ratio from 0.0009:1 to 0.0007:1 in weight with
respect to the total weight of composition;

said phendimetrazine bitartrate or phendimetrazine pamoate is in a ratio
from 0.004:1 to 0.13:1 in weight with respect to the total weight of composition;

said vitamin A is in a ratio from 0.5:1 to 1.8:1 in weight with respect to the
total weight of composition;

said vitamin B1, is in a ratio from 0.002:1 to 0.2:1 in weight with respect
to the total weight of composition;

said vitamin B6, is in a ratio from 0.05:1 to 0.2:1 in weight with respect to
the total weight of composition;

said vitamin E, is in a ratio from 0.09:1 to 1:1 in weight with respect to the
total weight of composition; and

said vitamin C, is in a ratio from 0.09:1 to 0.3:1 in weight with respect to
the total weight of composition.

32
C4

32. (New) The method as claim in claim 28, wherein in said administration of said composition, elements of said composition are in at least one of a set of ratios, said ratios including the set of; said sedative-ansiolityc agent is the benzodiazepine dipotassium chlorazepate in a ratio from 0.0005:1 to 0.03:1 in weight with respect to the total weight of composition;

said anoretic agent is selected from the group consisting of diethylpropione chlorhydrate, fenfluramine chlorhydrate, D-fenfluramine chlorhydrate, said anorectic agent being present in a ratio from 0.002:1 to 1.3:1 in weight with respect to the total weight of composition; and

said lipolytic agent is selected from the group consisting of the analogue of tiroxine, triiodotiroacetic acid which is present in a ratio from 0.0002:1 to 0.003:1 in weight with respect to the total weigh of composition.

33. (New) The method as claimed in claim 26, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

34. (New) The method as claimed in claim 27, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

35. (New) The method as claimed in claim 28, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of

approximately 70kg.

36. (New) The method as claimed in claim 29, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

37. (New) The method as claimed in claim 30, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

38. (New) The method as claimed in claim 31, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.

39. (New) The method as claimed in claim 32, wherein said administration of said composition is performed orally in doses from 7g to 23g per day to a patient of the weight of approximately 70kg.--

Remarks

Claims 1-25 are pending.

Claims 1-25 are subject to a restriction requirement.

Claims 1-25 have been cancelled.